Platelet-Coupled IL-2 Cell Injection is under clinical development by Zcapsule Pharmaceuticals (Shaoxing) and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Platelet-Coupled IL-2 Cell Injection’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Platelet-Coupled IL-2 Cell Injection overview
The therapeutic candidate (P-IL-2) is under development for the treatment of advanced malignant solid tumors. The therapeutic candidate comprises platelet coupled IL2 cells. It is administered through intravenous route and is being developed based on platelet delivery system, it acts by targeting IL2 receptor.
Zcapsule Pharmaceuticals (Shaoxing) overview
Zcapsule Pharmaceuticals (Shaoxing) (Zcapsule Pharmaceuticals) is engaged in providing clinical research and drug development services. Zcapsule Pharmaceuticals is headquartered in Shaoxing, Zhejiang, China.
For a complete picture of Platelet-Coupled IL-2 Cell Injection’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
